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An overview of current research and practice in rheumatic disease
•	Fatigue	is	as	common	and	severe	as		
pain	in	musculoskeletal	conditions
•	Validated	measures	of	fatigue	exist,		
with	limitations
•	Fatigue	has	a	multicausal	pathway,	with	
various	components	contributing	dif-	
ferent	amounts	in	different	patients	at	
different	times
•	Predictors	of	fatigue	may	include	inflam-
mation,	pain,	disability,	coping,	mood	and	
beliefs	about	illness
•	Evidence	for	interventions	to	ameliorate	
fatigue	is	not	abundant,	but	includes	
some	support	for	medications,	exercise,	
education	and	cognitive-behavioural	
therapy
•	Until	evidence	accumulates,	clinicians	
should	discuss	fatigue	with	patients,	
address	potential	and	perceived	causes	
and	support	self-management	strategies
•	Research	needs	to	address	mechanisms,	
measurement	and	management
INTRODUCTION
Fatigue is a frequent and distressing problem for 
many patients across all musculoskeletal conditions. 
It is often as severe and important as pain, yet there 
are few evidenced-based interventions available. The 
patient perspective on priorities for different symp-
toms has been a catalyst for the adoption of fatigue 
as a recommended measure in all clinical trials in 
rheumatoid arthritis (RA).1 This review covers the 
meaning, mechanisms, measurement and manage-
ment of fatigue, and suggests (with caveats) practical 
approaches for the clinician.
THE	MEANING	OF	FATIGUE	IN	
MUSCULOSKELETAL	CONDITIONS
Four qualitative studies have specifically explored 
fatigue in RA and fibromyalgia syndrome (FMS), while 
qualitative studies in other musculoskeletal con- 
ditions, although not focused on fatigue, suggest 
similar experiences. In total 76 RA patients were in- 
terviewed about fatigue, from the UK, USA and the 
Netherlands, and 25 women with FMS from Sweden, 
covering a range of demographic and disease vari- 
ables.2-5 These four studies yielded similar concepts 
and thus provide strong collective evidence on the 
nature, consequences and management of and atti-
tudes towards musculoskeletal fatigue.
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2The	nature	of	fatigue
For people with musculoskeletal conditions who are 
experiencing fatigue, it occurs on most days and varies 
in intensity and frequency, ranging from heaviness 
through weariness and on to exhaustion. Occasion-
ally, sudden and dramatic overwhelming ‘wipe-out’ 
comes on without warning, which has catastrophic 
consequences as people are forced to stop and lie 
down. Patients clearly differentiate between the ‘nor- 
mal’ tiredness they experienced before RA and RA 
exhaustion. Fatigue is considered equal to or worse 
than pain and is deemed unearned (and thus unfair 
and unpredictable) and unresolving. In all of these 
qualitative studies patients described not only physi-
cal fatigue but also cognitive fatigue, manifesting as an 
inability to think clearly, concentrate, or be motivated 
to do anything.
The consequences of fatigue affect every part of 
musculoskeletal patients’ lives, with far-reaching ef- 
fects on physical function, everyday tasks, work and 
leisure activities. Fatigue threatens traditional roles as 
patients struggle to maintain childcare, housework, 
social engagements and close relationships. Fatigue 
is the factor that most limits staying in paid employ-
ment, and causes patients to sacrifice enjoyable leis-
ure activities in order to save energy for perceived 
‘essential’ activities such as chores. The emotional 
consequences of fatigue are graphically described 
by patients as frustration, irritability, resentment and 
tearfulness.
Self-management of fatigue occurs through be- 
havioural means (resting, pacing, planning, using 
appliances), cognitive means (distraction, prioritis- 
ing, re-normalising life) and social means (seeking 
emotional and practical support). Despite these at- 
tempts, musculoskeletal patients view their fatigue 
as unmanageable and unresolving. They feel unsup-
ported by health professionals, and report that clin-
icians rarely ask about fatigue – thus patients believe 
clinicians are not interested in fatigue and so fail to 
raise it themselves. However, when patients did raise 
the problem of fatigue they perceived it was dis-
missed or they were offered generic advice that was 
unhelpful.
Fatigue in other long-term conditions (LTCs) has 
very similar physical and cognitive features, functional 
and emotional consequences and self-management 
strategies as in musculoskeletal conditions, but with 
some key differences.6,7 Multiple sclerosis (MS) fatigue 
is accompanied by neurological symptoms (nausea, 
dizziness, burning), which might indicate differences 
in disease-specific fatigue mechanisms.6 People with 
MS believe that fatigue exacerbates disease activity,6 
whereas people with RA perceive fatigue as a con-
sequence of disease activity.2 Cancer fatigue is seen by 
patients as predictable and linked to chemotherapy, 
and thus the onset of fatigue outside chemotherapy 
may cause fear of disease progression.7 Across all the 
studies, patients reported using self-management 
through trial and error (largely unsuccessful), while 
professional support was notable by its apparent 
absence.2-7
Normal tiredness is clearly differentiated from the 
features of fatigue related to an LTC by people in these 
studies. Fatigue in healthy working adults comprises 
similar physical and cognitive components, but is less 
profound, has a predictable cause (activity or stress), 
and is temporary and easily resolved through rest, 
while fatigue in LTCs is frequent, severe, unpredictable 
and unresolving.8 FMS is predominantly muscular 
pain plus fatigue and is diagnosed through tender 
point counts, differentiating it from chronic fatigue 
syndrome (CFS), which is predominantly fatigue plus 
pain – defined as medically unexplained fatigue of 
>6 months that is unrelated to exertion, not resolved 
by rest, and includes extreme activity reduction and 
≥4 of 8 other symptoms (e.g. lymphadenopathy).9 
This review covers fatigue in musculoskeletal con-
ditions, not CFS.
Fatigue	level	and	importance
Quantitative studies consistently show, often in large 
cohorts, that significant fatigue is common in RA 
(42–69%), osteoarthritis (OA) (41%), systemic lupus 
erythematosus (SLE) (90%), primary Sjögren’s syn- 
drome (PSS) (68%) and FMS (76%).10-13 Fatigue is 
often as severe as pain (e.g. in OA both pain and 
fatigue scoring 1.6 out of 3) and can be more severe 
than pain (e.g. in RA fatigue 1.6 out of 3, pain 1.4).10 
Fatigue differentiates between different levels of over-
all quality of life in RA, impacts on quality of life (in 
combination with pain and depression) and predicts 
deterioration in quality of life, and patients find it as 
difficult to cope with as pain.10,14,15 Therefore it is not 
surprising that patients place a high importance on 
fatigue.10,16,17
Future	research	into	the	meaning	of	
fatigue
While there are good qualitative studies exploring 
fatigue in RA and FMS, there are few in other mus-
culoskeletal conditions. Qualitative exploration of 
the physical and cognitive features of fatigue using 
mixed groups of people with various musculoskeletal 
conditions and LTCs might reveal different features 
that could indicate different fatigue mechanisms. 
Quantitative studies on the variations of fatigue 
during the day and the patterns of fatigue over the 
seasons may also help elucidate mechanisms and self-
management solutions.
3CAUSES	AND	PREDICTORS	OF	
FATIGUE (see Table 1)
Disease	activity/severity
Inflammatory markers of disease activity/severity tend 
to be weakly related to fatigue in RA and SLE in cross-
sectional studies.18 However, two longitudinal studies 
of people with SLE suggest that greater disease ac- 
tivity predicts higher fatigue after 1 year.19,20 When 
people with RA commence disease-modifying anti-
rheumatic drugs (DMARDs) or biologic therapy, the 
improvements in fatigue they report after 3–6 months 
are directly related to a reduction of composite dis-
ease activity and pain.21 In contrast, one longitudinal 
study of people with RA found that lower inflam-
mation (erythrocyte sedimentation rate – ESR) pre-
dicted higher fatigue after 1 year.22 This is a relative 
effect around the sample’s mean ESR, which can be 
high when sampling consecutive outpatients who can 
access emergency appointments during flares of their 
disease. On balance, the evidence suggests fatigue 
can be present regardless of disease activity/severity. 
However, many musculoskeletal conditions have dif-
ferent routine measures of disease activity/severity 
so it is not possible to generalise across conditions. 
Patient-reported disease activity/severity may differ 
from clinicians’ assessments18 and it is important to 
discuss patients’ concerns.
Demographics
Sex differences in fatigue are rarely evident in mus-
culoskeletal conditions. Women with RA may report 
higher fatigue than men with RA but this has only 
been supported by two of the many cross-sectional 
studies23,24 and no sex differences in the longitudi-
nal course of fatigue have been found. However, 
many observational studies of people with musculo-
skeletal conditions recruit mainly women for con-
venience; future studies must include more men 
with musculoskeletal conditions to test conclusively 
whether their fatigue trajectory differs from women’s. 
Evidence for a relationship between fatigue and time 
since diagnosis with a musculoskeletal condition is 
inconsistent. Fatigue has sometimes been found to 
be higher in people who have been diagnosed with 
RA for a longer time25,26 and sometimes higher among 
those with more recent RA onset.23 People with RA of 
any duration should therefore be included in inter- 
ventions aimed at avoiding the onset of fatigue or 
bolstering coping with existing fatigue. Age and eth-
nicity have not been reported to relate to fatigue in 
musculoskeletal conditions.
Musculoskeletal	pain,	functional	disability	
and	practical	support
On days when people with FMS, juvenile rheumatic 
diseases (JRDs), OA or RA have increased pain their 
fatigue is higher and this effect spills over to a main-
tained increase in fatigue the subsequent day.27-30 
Higher fatigue after 1 year is predicted by having 
less perceived help at home31 and greater functional 
disability among people with RA.31,32
Poor	mood,	stress	and	sleep	disruption
Mood disorders are common among people with 
musculoskeletal conditions33 and they have a com-
plex association with fatigue. Greater trait anxiety (the 
propensity to experience anxiety, rather than current 
clinical state) has been found to predict fatigue after 
1 year among people with RA.31 Furthermore, fatigue 
is higher among people with RA who have a lifetime 
history of mood disorder (i.e. current or previous 
clinical depression or generalised anxiety). As a result, 
their fatigue trajectories tend to be stable but elevated 
over 7 years as compared to people with RA with no 
previous mood disorder, whose fatigue trajectories 
start lower but tend to increase over time.33 When 
people with RA report greater distress (i.e. depressed 
mood) at annual assessment, fatigue is increased, 
although this increase is less pronounced for those 
who have greater aggregate distress across all as- 
sessments.33 Similarly, women with SLE who report 
increases in stress and depression between base-
line and an interim 9-month assessment experience 
higher fatigue after another 6 months.34 Poorer mood 
on a daily basis (i.e. decreases in positive affect and 
increases in negative affect) also relates to increased 
daily fatigue for people with FMS, JRDs, OA and 
RA,28-30 as does greater daily stress for children with 
JRDs.28,29 This pattern suggests that those people 
with musculoskeletal conditions who have generally 
lower distress have lower fatigue but are most sus-
ceptible to increased fatigue at times when they are 
experiencing distress. Nights of poorer sleep also 
relate to higher daily fatigue among people with RA 
or FMS.27,35 The pattern of fatigue across the day in RA 
and SLE is reported to be a J-shaped curve with levels 
decreasing across the morning and then building up 
to a peak in the late evening.35,36 This has implications 
for timing the assessment of fatigue in research and 
clinical practice. It would be optimal to ask patients 
to complete a structured log of their fatigue for a few 
days or weeks before their appointment.
Illness	perceptions,	symptom-control,	
self-efficacy	and	coping
Two longitudinal studies have explicitly tested Lev-
enthal’s Common-Sense Model (CSM) of beliefs about 
illness applied to fatigue among people with RA. 
Higher fatigue after 1 year is consistently predicted 
by perceptions that RA has severe consequences.22,37 
Lower self-efficacy (perceived personal control) over 
pain or mood/fatigue has been found to predict 
higher fatigue after 2 years in a further longitudinal 
study.38 Although the CSM predicts that coping 
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6mechanisms mediate the effect of perceptions on 
health outcomes, only one of the previous studies 
has identified a relationship between avoidant coping 
and fatigue after 1 year,37 and the effect of percep- 
tions of consequences remained significant along 
with that of coping style. Further evidence is required 
on this issue, particularly for conditions other than 
RA.
Future	research	into	the	mechanisms	of	
fatigue
There are several variables that are not covered in this 
review because only cross-sectional evidence exists 
for their link to fatigue in musculoskeletal conditions 
(e.g. headache, napping in the day and obesity). These 
variables require targeted longitudinal and daily ob- 
servation. Further patient perspective workshops at 
the international consensus group OMERACT (Out- 
come Measurements in Rheumatology Clinical Trials) 
could usefully provide important additions to this 
researcher-generated list of potential predictors of 
fatigue. 
MEASUREMENT	OF	FATIGUE
In the absence of good physical, behavioural or bio-
logical markers of fatigue, accurate assessment hinges 
on valid self-report measures. Reviews of fatigue scales 
have been conducted in SLE, arthritis and RA.12,39,40
Generic	single-item	fatigue	scales
Ordinal scales (e.g. none, mild, moderate, severe) dif-
ferentiate between RA patients with and without in- 
flammation, show fatigue fluctuations during the day, 
and correlate with other symptoms, although sensi-
tivity data are not evident in the literature.35,40 Numeri- 
cal rating scales (NRS) (e.g. 0–100) show daily vari-
ation (RA, OA, FMS) and reliability and correlate with 
other fatigue scales.30 Visual analogue scales (VAS; 
10 cm horizontal line with two descriptive anchors) 
were shown to be robust and sensitive for pain, but 
validation for fatigue VAS is based on accumulative 
RA data rather than specific validation studies. While 
accumulative data show fatigue VAS to have reason- 
able construct validity in RA, and to perform as well 
as longer fatigue questionnaires, reliability and sen-
sitivity data are inconsistent.40,41 In both PSS and SLE, 
fatigue VAS correlate significantly with the Chalder 
Fatigue Scale, and differentiate between patients 
and controls (the Chalder Fatigue Scale did not dif-
ferentiate).42 However, a review showed that out of 
26 VAS identified as used for RA fatigue only three 
were identical, which limits comparison between 
studies; therefore a standardised RA fatigue VAS is 
currently being validated.40,43
Generic	multi-item	fatigue	scales
Given that fatigue is present in many LTCs, generic 
scales might capture musculoskeletal fatigue and fa- 
cilitate comparison across conditions. The Medical 
Outcomes Studies 36-item Short-Form questionnaire 
(SF36) includes a 4-item vitality subscale (pep, en- 
ergy, worn out, tired),44 which differentiates between 
healthy controls and people with PSS or ankylosing 
spondylitis (AS).42,45 While many RA studies support 
validation and sensitivity to change for the SF36 vi- 
tality subscale in RA, in other studies the SF36 shows 
people with RA as having more vitality than people 
without illness, has inconsistent correlation with in- 
flammatory markers, and does not easily distinguish 
between depression and RA fatigue.40 Conceptually, 
the absence of vitality may not be a measure of fatigue, 
as it is possible to be neither full of pep yet not fa- 
tigued (i.e. neutral). The SF36 vitality subscale would 
benefit from further validation in RA and other rheu- 
matic diseases.40 The Multidimensional Fatigue In- 
ventory (MFI) comprises 5 fatigue subscales (general, 
physical, activity, motivation, mental), was developed 
in Dutch cancer and CFS patients, and has been used 
in RA, AS, FMS and PSS.46-49 Some items may poten-
tially be confounded by disability or inflammatory 
activity (e.g. ‘Physically I feel only able to do a little’), 
and the MFI did not differentiate between people with 
RA and healthy controls on 2 of the 5 subscales.40 The 
Functional Assessment of Chronic Illness Therapy 
scale was developed for USA cancer patients and 
has a 13-item fatigue subscale (FACIT-F), validated 
in RA and psoriatic arthritis (PsA).50,51 It shows good 
internal consistency, convergent validity with disease 
activity, and (in RA) sensitivity to change. However, 
some items may be irrelevant in arthritis (e.g. being 
too tired to eat) or confounded by disability (e.g. 
needing help to perform activities).
Disease-specific	scales	
Disease-specific scales might address the concern that 
generic scales may measure irrelevant, confounding 
or insufficient items. The Fibromyalgia Impact Ques-
tionnaire (FIQ)52 comprises 8 subscales, one of which 
is fatigue. This VAS subscale was not validated against 
a gold standard fatigue scale, but shows reliability 
over 1 week and has been used in many FMS studies. 
The Multidimensional Assessment of Fatigue (MAF) 
scale is RA-specific and was developed from a USA 
cancer fatigue scale.53 It has 16 questions measuring 
4 physical fatigue dimensions (fatigue severity, dis- 
tress, impact and timing) and yields a global score. 
There is good evidence of construct validity, dis-
crimination between patients and controls, internal 
consistency and sensitivity to change.39,40 However, it 
lacks cognitive items and (anecdotally) the question-
naire layout leads patients to answer the questions in 
terms of disability rather than fatigue. It is possible 
7that different dimensions of fatigue might respond 
differently to an intervention, and therefore a new 
RA-specific fatigue scale with a range of subscales, 
including cognition, is being developed and vali-
dated in the UK.54 The Fatigue and Discomfort Ques-
tionnaire, developed with UK patients with PSS, in- 
cludes a Profile of Fatigue (ProF), a stand-alone scale 
with 16 items comprising a somatic fatigue domain 
(needing rest, poor starting, low stamina, weak 
muscles) and a mental fatigue domain (poor memory, 
mental fatigue).13 A study comparing the ProF with the 
generic MFI showed that both scales demonstrated 
good internal consistency, and were strongly related, 
but that the ProF has a stronger internal structure.48 
Fifteen fatigue instruments were reviewed in SLE and 
the Fatigue Severity Scale (FSS) was recommended.12 
This USA-originated scale comprises 9 items on fa- 
tigue impact, differentiates people with SLE from 
controls, shows internal reliability, construct validity 
and sensitivity to change, and has also been used in 
FMS.39 While some of the assessment scales used in 
AS and OA contain fatigue items, they have not been 
validated for producing identifiable fatigue scores, 
although there is some evidence for an AS fatigue 
item.45 In summary, while there is some evidence for 
the validity of some fatigue scales in musculoskeletal 
conditions, scales should be selected with care.
The smallest change in fatigue that someone with 
SLE or RA might notice (minimal clinically important 
difference – MCID) has been explored. On a scale of 
0–100, evidence suggests that a difference of 7–14 
points is recognisable by people with SLE as being 
a significant change, and 10 points in people with 
RA.55,56
Future	research	into	the	measurement	of	
fatigue
Measures with valid subscales are needed to explore 
different facets of fatigue, as these might be separately 
changed by different interventions (e.g. a behavioural 
intervention might not change fatigue severity but 
may well ameliorate its impact). Standardised fatigue 
VAS and NRS should be formally compared as the 
trend for transforming VAS into boxes, numbers or 
circles for ease of on-line computer-based studies, 
or for scanning data into spreadsheets, may alter the 
psychometric properties of the VAS.
MANAGEMENT	OF	FATIGUE:	
EVIDENCE	FROM	RANDOMISED	
CONTROLLED	TRIALS
Medication
DMARDs and biologic agents, used both individually 
and in various combinations, can improve fatigue in 
inflammatory musculoskeletal conditions, as is re- 
ported in many randomised controlled trials (RCTs), 
Cochrane reviews and overviews,57 although the mech-
anism may be through association with changes in 
pain rather than inflammation.21 A systematic review 
shows antidepressants may reduce fatigue in FMS.58 
However, fatigue commonly occurs without inflam-
mation or depression and therefore RCT evidence 
for non-pharmacological interventions was explored. 
Relatively few RCTs could be identified.
Exercise
Graded exercise therapy improved fatigue in people 
with SLE immediately post-intervention compared to 
relaxation or usual care (n=93, SF36 vitality 51 vs 41 
and 34, p=0.015) and was maintained at 3 months.59 
Home aerobic training for people with RA showed 
only a trend toward fatigue improvement60 but 
group exercise in people with self-reported arthritis 
(8 weeks of 2 x 1-hour sessions) showed an improve-
ment in fatigue post-intervention compared to con-
trols (n=346, VAS 35.4 vs 43.7, p=0.01), which was 
maintained at 6 months.61 A Cochrane review of ex- 
ercise in FMS found 16 studies in which fatigue was 
measured, and concluded that effects on fatigue were 
unknown (moderate quality evidence).62
Education	or	self-management	
programmes
A 2003 Cochrane review of RA education programmes 
did not examine effects on fatigue, but an RCT of the 
Arthritis Self-Management Programme in patients with 
a GP diagnosis of ‘arthritis’ reported a trend to fatigue 
reduction at 4 months, which reached significance at 
12 months, compared to control (n=554, VAS 0–10 
–0.44 vs +0.05, p=0.02).63 
Psychological	interventions
A systematic review of psychological interventions in 
RA up to 2001 analysed 25 RCTs but none addressed 
fatigue. Cognitive-behavioural therapy (CBT) ad- 
dresses the links between thoughts or beliefs, feelings 
and behaviours, and uses individualised goal-setting 
and cognitive restructuring to help patients make 
desired changes in behaviour. In people with early 
RA who were experiencing psychological distress, 
CBT resulted in a significant improvement in fatigue 
post-intervention, which was maintained at 6 months 
(n=59, effect sizes 0.55, 0.48).64 Although CBT re- 
sulted in an improvement in fatigue in people with 
SLE, this was not significantly greater than symptom 
monitoring or usual care.65 A systematic review of 13 
RCTs of mind-body therapies in FMS found a single 
trial of hypnotherapy, with inconclusive evidence 
of effects on fatigue.66 Written emotional disclosure 
(about traumatic events, deep thoughts and feelings, 
or benefit-finding) reduced fatigue at 3–4 months 
compared to factual writing or usual care in people 
8with RA or SLE (n=75, VAS 40.9 and 57.8 vs 75.8)67 
and in people with FMS (n=92, SF36 –13.7 vs –3.7, 
p=0.05),68 although this effect was lost by 10 months 
in FMS. A psychological intervention combining self- 
efficacy, social support, problem-solving and repeated 
counselling for people with SLE and their partners 
reduced fatigue at 12 months (n=122, 10-point scale 
5.1 vs 6.3, p=0.02).69 A combination of CBT with edu-
cation and exercise in FMS resulted in an improve-
ment in fatigue at 4 months (n=183, 10-point scale 
–0.61 vs +0.09, p=0.02).70
Other	therapies
A large study of acupuncture versus three different 
types of sham acupuncture (n=100, 24 treatments) 
showed no effect on fatigue in FMS.71 While homoe-
opathy improved pain and quality of life in FMS 
patients compared to placebo, it did not change fa- 
tigue (n=62),72 and the positive effects of spa therapy 
on FMS fatigue compared to usual care were lost after 
2 weeks (n=30).73
In summary, evidence for non-pharmacological inter-
ventions is constrained by the small number of RCTs 
(some of which have small sample sizes or are not 
of high quality), the use of unvalidated scales (often 
VAS), and the fact that they are often not primarily 
aimed at or powered for fatigue. There is some evi-
dence for exercise, education, CBT and emotional dis- 
closure in the short to medium term.
Future	research	into	the	management	of	
fatigue
Future research needs to address whether, rather 
than changing the severity of fatigue per se, we might 
be able to change beliefs about coping with fatigue, 
or change ability to participate in socialising despite 
continuing fatigue, and thus reduce the impact of per- 
sistent fatigue. Suggestions that interventions work for 
particular sub-groups should be pursued (e.g. early 
disease, distressed patients).64 Where there are com-
plex intervention approaches, evidence on the con- 
tribution of different components (e.g. goal-setting, 
energy conservation, cognitive restructuring) would 
be helpful. Studies should have fatigue as their primary 
outcome, be well designed, robust, and adequately 
powered, and should address interventions that can 
be easily translated into clinical practice (e.g. few rheu- 
matology departments have a clinical or health psy-
chologist within their team). In addition, long-term 
follow-up and the use of booster sessions should be 
explored.
CONCEPTS	OF	FATIGUE	IN	
MUSCULOSKELETAL	CONDITIONS
There is no universally-accepted definition of fatigue 
in either health or illness, but conceptual and theor-
etical frameworks for fatigue in cancer and MS are 
being developed to help classify fatigue so as to en- 
hance measurement and intervention.74,75 A frame-
work for fatigue in musculoskeletal conditions should 
be able to incorporate classifications of fatigue (e.g. 
physical, emotional, cognitive, motivational), define 
incremental fatigue states (e.g. tiredness, weariness, 
exhaustion), account for different manifestations (e.g. 
gradual onset, acute wipe-out), identify potential 
drivers (e.g. biological, psychological, social), allow 
for cyclical states (e.g. fatigue leading to depression, 
which fuels further fatigue) and sit within a theoreti-
cal framework to exemplify opportunities for inter- 
vention (e.g. biopsychosocial or cognitive-behavioural 
frameworks). A conceptual and theoretical framework 
is currently being developed for fatigue in musculo-
skeletal conditions (by the Fatigue in RA Group (FRAG); 
contact sarah.hewlett@uwe.ac.uk).
APPLICATION	OF	THESE	FINDINGS	
TO	CLINICAL	PRACTICE
Mood changes and illness perceptions have the most 
observational evidence of an association with fatigue 
in musculoskeletal conditions. These issues could be 
applied as ‘yellow flags’ for identifying individuals 
who are at risk of the onset of fatigue, or are develop-
ing persistent fatigue despite pharmacological man-
agement (e.g. the use of DMARDs to control disease 
activity).
With the caveat that existing evidence for interven-
tions is limited, clinicians might consider the follow-
ing approaches to such patients:
•	 discussing	fatigue	with	patients,	which	may	help	
them to feel their symptom and associated distress 
are validated
•	 checking	for	and	treating	anaemia,	thyroid	dysfunc-
tion, diabetes or depression if appropriate
•	 providing	literature	that	explains	fatigue	(e.g.	the	
arc patient leaflet ‘Fatigue and Arthritis’, www.arc.
org.uk/arthinfo/patpubs/6269/6269.asp)
•	 developing	fatigue	self-management	strategies	within	
existing education programmes
•	 identifying	a	team	member	to	specialise	in	fatigue	
(and refer patient to them)
•	 utilising	a	fatigue	diagram	to	explore	patient’s	per-
ceived areas for intervention (untested, Figure 1)
•	 considering	use	of	daily	diaries	to	identify	behav-
iours such as ‘boom and bust’ or excessive rest, ac-
companied by supported, individualised goal-setting 
to change behaviour.
9CONCLUSION
The current interest in fatigue in musculoskeletal con-
ditions is a testament to the voice of the patient per-
spective in outcome measurement. Further research 
is needed into the meaning, mechanisms, measure- 
ment and management of fatigue. While debate con-
tinues about whether fatigue is specific to inflamma-
tory arthritis or is simply the fatigue of an LTC, patients 
still have to manage this difficult symptom. Research 
is continuing internationally, with a long-term aim of 
developing an evidence-based treatment algorithm.
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